Lung cancer remains the leading cause of cancer-related death with poor survival due to the late stage at which lung cancer is typically diagnosed. Given the clinical burden from lung cancer and the relatively favorable survival associated with early-stage lung cancer, biomarkers for early detection of lung cancer are of important potential clinical benefit.
- A global lung cancer serum biomarker discovery study was done, using liquid chromatography-tandem mass spectrometry in a set of pooled non-small cell lung cancer case sera and matched controls. A set of candidate serum biomarkers with differential abundance across the lung cancer case/control pools was identified, which after validation could improve lung cancer early detection (Zeng X, et. al., J Thorac Oncol. 6:725-34, 2011).
|Gopalakrishnan, Vanathi, PhD
|Weissfeld, Joel, MD, MPH
|Socinski, Mark, MD
|Wilson, David, MD, MPH